Breckenridge Recalls Duloxetine Capsules Over Chemical Hazard
Breckenridge Pharmaceutical, Inc. recalled 7,389 bottles of Duloxetine Delayed-Release Capsules on November 24, 2025. The recall stems from CGMP deviations and the presence of N-nitroso-duloxetine impurity above FDA limits. Consumers should stop using the product immediately and contact healthcare providers for guidance.
About This Product
Duloxetine Delayed-Release Capsules are a prescription medication used to treat major depressive disorder, generalized anxiety disorder, fibromyalgia, and neuropathic pain. Patients buy this medication to manage chronic pain and mood disorders.
Why This Is Dangerous
The presence of N-nitroso-duloxetine above FDA limits raises concerns about potential carcinogenic effects, making the product unsafe for consumption.
Industry Context
This recall is not part of a broader industry pattern.
Real-World Impact
Consumers are urged to stop using the product immediately to avoid potential health risks. This recall can cause inconvenience for those relying on Duloxetine for treatment.
Practical Guidance
How to identify if yours is affected
- Check the lot number on your capsule bottle.
- Verify the expiration date.
- Identify if your bottle matches Lot #: 240534C or 240977C.
Where to find product info
The lot number and expiration date are typically found on the label of the bottle.
What timeline to expect
Expect a timeline of 4-6 weeks for refund processing after contacting the manufacturer.
If the manufacturer is unresponsive
- Follow up with Breckenridge Pharmaceutical, Inc. if they do not respond promptly.
- Document all communications and consider filing a complaint with the FDA.
How to prevent similar issues
- Look for FDA approval and certifications when purchasing medications.
- Be cautious of product recalls and check for updates regularly.
- Consult with healthcare providers about alternative medications.
Documentation advice
Keep receipts, correspondence, and any documentation related to the recall for your records.